Scientists from Germany have designed a new complex which inhibits enzymes and reduces tumour cell growth.
The drug complex consists of N-heterocyclic carbene ligands coordinated to a ruthenium metal centre. Ruthenium N-heterocyclic carbene compounds are largely popular due to their catalytic properties but very little attention has been paid to the biological activity of these species.
Why not download the article now to find out what the team did…?
Evaluation of arene ruthenium(II) N-heterocyclic carbene complexes as organometallics interacting with thiol and selenol containing biomolecules
Luciano Oehninger, Maria Stefanopoulou, Hamed Alborzinia, Julia Schur, Stephanie Ludewig, Kazuhiko Namikawa, Alvaro Muñoz-Castro, Reinhard W. Köster, Knut Baumann, Stefan Wölfl, William S. Sheldrick and Ingo Ott
